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16 The Journal of Thoracic and Cardiobjective: The 1997 version of the TNM staging system for lung cancer has several
rognostic problems. Among these, the overlapping survival of stages IB and IIA is
he most serious. We performed this retrospective study to test a revised TNM
taging system for lung cancer.
ethods: We revised the T1 descriptor definition and stage grouping for testing as
ollows. According to the greatest tumor diameter, T1 tumors were divided into T1a
umors (2.0 cm) and T1b tumors (2.1-3.0 cm). With these descriptors, new IA, IB,
nd IIA stages were defined as T1a N0 M0, T1b N0 M0, and T2 N0 M0  T1 N1
0, respectively. For 6644 patients with histologically non–small cell lung cancers
esected in 1994 and reported in the Japanese Lung Cancer Registry Study, the
urvivals and prognostic difference between neighboring stages were studied.
esults: The 5-year survival of the entire population was 52.6%. In the clinical
etting, the 5-year survivals of the new IA, new IB, new IIA, IIB, IIIA, IIIB, and IV
tages were 77.5%, 69.3%, 49.8%, 40.6%, 35.8%, 28.0%, and 20.8%, respectively.
n the pathologic setting, they were 83.7%, 76.0%, 60.0%, 42.2%, 29.8%, 19.3%,
nd 20.0%, respectively. For both clinical and pathologic settings, differences
etween all neighboring stages were statistically significant, except for that between
IIB and IV.
onclusion: Subcategorization of T1 and minor changes in stage grouping results in
system with significant differences in prognosis between neighboring stages. The
nification of stages IB and IIA, especially, improves the discriminatory power of
he staging system.
 
he sixth edition of the International Union Against Cancer (UICC) 
staging system for lung cancer has been available worldwide since 11
and the next revision is scheduled for 2009. In a few years, the thoracic
ncologic community must finalize a review of the current system and possible
hanges to it to identify existing and potential problems. As is well known, an
mportant objective of the TNM staging system is to provide a differential prognosis
or patients with similar “stages” of the disease, applicable worldwide. As such,
verlapping prognoses for patients with different stages must be avoided.
For these purposes, the Japan Lung Cancer Society and the Japanese Association
or Chest Surgery established an ad hoc task force, the Japanese Joint Committee of
ung Cancer Registry, and performed a large-scale retrospective study of the
rimary lung neoplasms resected in 1994 at the 320 certified teaching hospitals in
apan. We received replies from 303 institutions (94.7%) that included data forms
rom 7408 patients. The results of a detailed analysis of 6644 histologically typed
on–small cell lung cancers (NSCLCs) have been published previously, with a
ritique of the current system.2 An important failing of the current staging system
vascular Surgery ● August 2006
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G
TSs that no difference in prognosis between stages IB an
s seen in either the clinical or the pathologic setting
urvival curves of patients in both groups are essent
uperimposed for their entire length. The purpose of 
tudy was therefore to improve the TNM staging system
odifying the T descriptors and stage grouping in the 
tages and then to test the new staging retrospecti
gainst the Japanese Lung Cancer Registry.
ethods
atients
nly primary lung neoplasms that had been resected in 19
ertified teaching hospitals in Japan were considered, to ensu
ollow-up period of at least 5 years. All cases were staged a
ng to the sixth edition of the UICC TNM staging system.1 The
etails of this registry study have been published elsewhere2 In
rief, the registry included 7408 patients; among them, data 
644 patients (89.7%) with histologically typed NSCLC w
nalyzed. For the preoperative evaluation of the surgical ca
ates, the standard workup at the time of resection (1994)
erformed, in which at least the chest radiography and comp
omography (CT) were performed for all the patients. The u
ediastinoscopy, brain CT (or magnetic resonance imaging), b
can, or abdominal CT (ultrasonography) was considered if 
ssary. Positron emission tomography was not routinely use
994. The same population was used for this simulation study
atients included 4601 men (69.6%) and 2010 women (30.
ex was not noted in the records of 33 patients. Patients ran
ge from 19 to 90 years, with an average of 64.5 year
istologic type of the tumor was described according to the W
ealth Organization classification.3 The most common histologi
ype was adenocarcinoma in 3922 patients (59.0%), followed
quamous cell carcinoma in 2300 (34.6%), large cell carcinom
45 (3.7%), and adenosquamous carcinoma in 177 (2.7%).
imulation
n the previous study, the 5-year survivals by stage for clinic
athologic settings were as follows: stage IA, 72.1% and 79
B, 49.9% and 60.1%); IIA, 48.7% and 59.9%; IIB, 40.6%
2.2%; IIIA, 35.8% and 29.8%; IIIB, 28.0% and 19.3%; an
0.8% and 20.0%.2 No statistically significant difference in s-
ival was observed between stages IB and IIA in either the c
r the pathologic setting. On the basis of these results, we
roposed the following new definition of T descriptors and 
rouping. All the other definitions of T, N, and M descripto
ell as the stage groupings, remained unchanged.
T descriptors. T1 tumors were originally defined as those 3
Abbreviations and Acronyms
BAC  bronchioloalveolar carcinoma
CT  computed tomography
NSCLC non–small cell lung cancer
UICC  International Union Against Cancerr smaller in greatest diameter, surrounded by lung or visceral.
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leura, without bronchoscopic evidence of invasion more proxi
han the lobar bronchus (not in the main bronchus).1 In our
evision to the staging system, T1 tumors were divided into
nd T1b subcategories according to size. T1a tumors were de
s 2.0 cm or smaller in greatest diameter; T1b tumors were d
s 2.1 to 3.0 cm in greatest diameter. Other T descriptors rem
nchanged.
Stage grouping. In our revised system, we defined T1a N0
s new stage IA and T1b N0 M0 as new stage IB. T2 N0 M
B) and T1 N1 M0 (stage IIA) were merged as new stage I
ther stage groupings remained unchanged.
tatistical Analysis
he survival time was defined as the date of surgery to the last
ollow-up date. The survival curves were estimated according to
hese new stage definitions for the same population with histolog-
cally typed NSCLC as in the previous study, and the differences
n survival between neighboring stages was tested to evaluate the
ppropriateness of stage distribution. The survival curves were
stimated by the Kaplan-Meier method, and the difference in
urvival was tested by the log-rank test.
esults
linical Setting
he 5-year survival for the entire population of 6644 pa-
ients was 52.6%. In the clinical setting, prognostic data
ere not available for 226 patients (3.4%). The distribution
f patients and 5-year survivals are presented in Tab
he stages new I, new II, III, and IV comprised 34.3%,
8.0%, 25.5%, and 2.3% of the total, respectively. Survival
urves according to the clinical stage are shown in Figu
he 5-year survivals for patients with tumors classified as
ew IA, new IB, and new IIA were 77.5%, 69.3%, and
9.8%, respectively (Table 1). The differences in surv
etween neighboring stages were tested. The differences
etween all neighboring stages were statistically significant
P  .001), except for that between IIIB and IV (P 
ABLE 1. Five-year survivals according to clinical stage,
ncluding new IA, new IB, and new IIA stages*
linical stage n (%) 5-y Survival (%)
Difference in
survival†
A 1204 (18.8%) 77.5 0.001
B 993 (15.5%) 69.3 0
IA 1692 (26.4%) 49.8 0
IB 746 (11.6%) 40.6 0.0439
IIA 1270 (19.8%) 35.8 0
IIB 366 (5.7%) 28.0 0.1577
V 147 (2.3%) 20.8 —
otal 6418 (100%) — —
There were 226 missing data points (3.4% of the total). †Significance of
ifference in survival between this stage and next higher stage (P value).1577).
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TSathologic Setting
n the pathologic setting, prognostic data were not avai
or 58 patients (0.9%). The distribution of patients 
-year survival rates are presented in Table 2. The s
ew I, new II, III, and IV comprised 29.7%, 36.6%, 2
nd 3.9%, respectively. Survival curves according to 
athologic stage are shown in Figure 2. The 5-year surv
f patients with disease classified as new IA, new IB
ew IIA were 83.7%, 76.0%, and 60.0%, respectively (T
). The differences in survival between neighboring sta
ere tested. The differences between all neighboring sta
ere statistically significant (P  .001), except for tha
etween IIIB and IV (P  .8833).
igure 1. Survival curves for clinical setting with new IA, new IB,
nd new IIA stages: 5-year survivals were 77.5% for new IA (n 
204), 69.3% for new IB (n  993), 49.8% for new IIA (n  1692),
0.6% for IIB (n  746), 35.8% for IIIA (n  1270), 28.0% for IIIB
n  366), and 20.8% for IV (n  147). Differences in survival
etween neighboring stages were significant (P < .001) except
hat between IIIB and IV (P  .1577).
ABLE 2. Five-year survivals according to the pathologic
tage, including new IA, new IB, and new IIA stages*
athologic stage n (%) 5-y Survival (%)
Difference in
survival†
A 1065 (16.2%) 83.7 0.001
B 886 (13.5%) 76.0 0
IA 1650 (25.1%) 60.0 0
IB 757 (11.5%) 42.2 0
IIA 1250 (19.0%) 29.8 0
IIB 719 (10.9%) 19.3 0.8833
V 259 (3.9%) 20.0 —
otal 6586 (100%) — —
here were 58 missing data points (0.9%) of the total. †Significance of s
.ifference in survival between this stage and next higher stage (P value).
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iscussion
he retrospective survey by the Japanese Joint Committee
f Lung Cancer Registry was one of the largest studies of its
ype ever performed.2 For NSCLC histologic types, t
emographic and prognostic data of 6644 patients were
nalyzed. The most remarkable finding in that study was the
verlapping prognoses of patients with stage IB and IIA
ancer. Despite the different stage categories, the survival
urves of stages IB and IIA were almost identical, with
-year survivals of 49.9% versus 48.7% (clinical stage) and
0.1% versus 59.9% (pathologic stage), respectively. No
ignificant difference in survival was observed in either the
linical or the pathologic setting. Similar results have been
eported in the past, raising a concern about the current
NM staging system.4-7 These findings clearly indicate
hat the current stages IB and IIA should be merged to-
ether, either as a new stage IB or a new stage IIA. There
ould be two alternative ways to name the merged IB 
IA category, as new IB or new IIA. Considering that this
erged category has a 5-year survival of only approxi-
ately 50% in a clinical setting, it should be a part of stage
I and not of stage I.
Separation of the subgroup of patients with worse prog-
oses in stage IB (T2 N0 M0) has been attempted previously.
arger tumors, such as those at least 5 or 6 cm in diameter,
ave been proposed for an upgrade to T3.8,9 Tumors larger
han 6 cm in our current data set comprised 12.1% (n  341)
f the entire group of T2 lesions (n  2809), so even if these
umors were transferred to the T3 category, the prognostic
ifference between stages IB and IIA would remain un-
igure 2. Survival curves for pathologic setting with new IA, new
B, and new IIA stages: 5-year survivals were 83.7% for new IA
n  1065), 76.0% for new IB (n  886), 60.0% for new IIA (n 
650), 42.2% for IIB (n  757), 29.8% for IIIA (n  1250), 19.3%
or IIIB (n  719), and 20.0% for IV (n  259). Differences in
urvival between neighboring stages were significant (P <001) except that between IIIB and IV (P  .8833).
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G
TShanged. Considering the small percentage of large tumor
2 category, the impact of the exclusion of the large
ubgroup on the prognostic difference between stages IB 
IA seemed to be limited as a whole.
According to the UICC TNM staging system, T1 tum
ere originally defined as those 3 cm or smaller in gr
iameter, surrounded by lung or visceral pleura, 
ithout bronchoscopic evidence of invasion more pr
mal than the lobar bronchus (not in the main bronc
owever, the T1 category is heterogeneous. Many gro
ave performed retrospective studies examining the 
ect of tumor size on stage, curability, and patient surviv
lthough controversy remains as to the role of size w
he T1 category. Ishida and colleagues,10 Read and cowork-
rs,11 Warren and Faber,12 Padilla and colleagues,13 Koike
nd associates,14 and Gajra and coworkers15 uniformly re-
orted a significant difference in survival between patien
ith tumors no larger than 2.0 cm and those with tumors
.0 cm. Flieder and colleagues16 found that NSCLC larger th
.0 cm was twice as likely to have nodal metastases
arcinomas no larger than 2.0 cm. M o s t o f t h e reports used
he 2.0-cm cutoff point. This study also identified a si
cant difference in survival between T1a N0 M0 and T1
0 for both clinical and pathologic settings in larger 
lations, and thus the subdivision of the T1 N0 M0 
roup according to the 2.0-cm cutoff point might be 
ustified. Although a numeric imbalance between T1a (2.0
m) and T1b (2.0-3.0 cm) might be expected, the a
umbers of patients in this study were well balanced: 
1a N0 M0 versus 993 T1b N0 M0 for the clinical 
nd 1065 T1a N0 M0 versus 886 T1b N0 M0 fo
athologic setting. Therefore the subdivision of stage 
umor size at a 2.0-cm cutoff point seems to be reali
However, because of the recent improvement of 
mages and the advent of low-dose CT screening progr
he noninvasive form of adenocarcinoma, bronchioloalve
ar carcinoma (BAC), is often included in the small
ategory. According to the World Health Organization 
ologic classification, BAC is defined as an adenocarcino
ith a pure bronchioloalveolar growth pattern and no 
ence of stromal, vascular, or pleural invasion. The su
rognosis after adequate resection of BAC is already 
ecognized.17-19 These noninvasive BACs should therefo
e newly termed as Tis and excluded from the T1 cate
he prognostic difference between T1a N0 M0 and T1b
0 thus might change in the future.
In conclusion, stages IB and IIA in the existing UICC 
ystem should be merged (as a new stage IIA) because they
ave essentially the same prognosis. Stage IA tumors should
e divided into stages new IA and new IB with a tumor cutoff
ize of 2.0 cm (T1a tumors2.0 cm, T1b tumors 2.1-3.0 cm).
AC should be considered Tis and excluded from the T1
ategory. With these minor revisions, the prognostic distribu-
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ion by stage would be better balanced, with significant differ-
nces between neighboring stages.
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